Subscribe: Market Wire - Pharmaceuticals and Biotech: Biotech
http://img.marketwire.com/rss/mwPBBI.rss
Added By: Feedage Forager Feedage Grade B rated
Language: English
Tags:
announced  announces  company  development  ended march  marketwired  nasdaq  new  quarter  results  today announced  today 
Rate this Feed
Rate this feedRate this feedRate this feedRate this feedRate this feed
Rate this feed 1 starRate this feed 2 starRate this feed 3 starRate this feed 4 starRate this feed 5 star

Comments (0)

Feed Details and Statistics Feed Statistics
Preview: Market Wire - Pharmaceuticals and Biotech: Biotech

Marketwired - Biotech



Marketwired - Biotech



Last Build Date: Sat, 27 May 2017 12:31:49 EDT

Copyright: Copyright: (C) Marketwired
 



Phenomenex Opens New Gas Chromatography Research and Manufacturing Facility

Sat, 27 May 2017 12:00:00 EDT

TORRANCE, CA--(Marketwired - May 27, 2017) - Phenomenex Inc., a global leader in the research and manufacture of advanced technologies for the separation sciences, announces the opening of a new manufacturing and development facility dedicated to the company's gas chromatography (GC) columns, marketed under the ZebronT brand name. The 15,000-square-foot facility, which was designed and extensively renovated specifically for Phenomenex, is located in the Sacramento, Calif. suburb of El Dorado Hills. Prior to the expansion, GC products were manufactured in Sutter Creek, Calif.




New Family of Zebron(TM) GC Columns for Fast, Highly Selective FAME Analysis

Fri, 26 May 2017 17:12:54 EDT

TORRANCE, CA--(Marketwired - May 26, 2017) - Phenomenex Inc., a global leader in the research, design and manufacture of advanced technologies for the separation sciences, introduces a trio of ZebronT GC columns specially developed for the analysis of fatty acid methyl esters (FAME) in food. Identification and measurement of these compounds in food products such as cheese, peanut butter, infant formula, cooking oils and oil-based nutritional supplements is increasingly important in meeting labeling requirements and testing for product adulteration.




Trillium Announces Voting Results from the Annual Meeting of Shareholders

Fri, 26 May 2017 16:05:00 EDT

TORONTO, ONTARIO--(Marketwired - May 26, 2017) - Trillium Therapeutics Inc. (NASDAQ:TRIL)(TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced the voting results from its Annual Meeting of shareholders held today. The results of the director elections were as follows:




Tronox to become the largest producer of TiO2 in the world upon the acquisition of Cristal

Fri, 26 May 2017 10:37:21 EDT

Tronox Limited announces a definitive agreement to acquire the Titanium Dioxide production assets of Cristal (The National Titanium Dioxide Company Limited)




Blue Diamond Ventures Inc. announces Strategic Partnership

Fri, 26 May 2017 09:55:37 EDT

Eltron R & D and BLDV join forces to make an ImPAAct(TM) (PAA) in the Cannabis Industry




EnWave Announces 2017 Second Quarter Consolidated Interim Financial Results

Fri, 26 May 2017 09:00:00 EDT

VANCOUVER, BC --(Marketwired - May 26, 2017) - EnWave Corporation (TSX VENTURE: ENW) (FRANKFURT: E4U) ("EnWave", or the "Company") today reported the Company's consolidated interim financial results for the second quarter ended March 31, 2017. The Company reported consolidated revenue of $4,183,000, and a consolidated net loss of $779,000 for the second quarter of fiscal year 2017. Non-cash items included in the consolidated net loss were $339,000 of stock based compensation expense and $220,000 of amortization expense related to intangible assets.




Amedica Announces Delayed Filing of Quarterly Report on Form 10-Q and Receipt of Nasdaq Letter

Fri, 26 May 2017 09:00:00 EDT

SALT LAKE CITY, UT--(Marketwired - May 26, 2017) - Amedica Corporation (NASDAQ: AMDA), an innovative biomaterial company which develops and manufactures silicon nitride as a platform for biomedical applications, announced today that it has delayed the filing of its Quarterly Report on Form 10-Q for the quarter ended March 31, 2017 ("Form 10-Q").




Trillium Announces Pricing of US$30.0 Million Public Offering of Common Shares and Series II Non-Voting Convertible First Preference Shares

Fri, 26 May 2017 08:30:00 EDT

TORONTO, ONTARIO--(Marketwired - May 26, 2017) - Trillium Therapeutics Inc. (NASDAQ:TRIL)(TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has priced its previously announced underwritten public offering of 2,750,000 common shares and 3,250,000 Series II Non-Voting Convertible First Preferred Shares. The common shares are being sold at a public offering price of US$5.00 per share and the Series II Non-Voting Convertible First Preferred Shares are being sold at a public offering price of US$5.00 per share. The gross proceeds to the Company from this offering are expected to be approximately US$30.0 million, before deducting underwriting discounts and commissions and other estimated offering expenses. The Company has also granted the underwriters a 30-day option to purchase from it up to an additional 412,500 common shares on the same terms and conditions. The offering is expected to close on June 1, 2017, subject to the satisfaction of customary closing conditions.




Cannabis Science, Inc. Receives U.S. Federal Government Clearance to Receive U.S. Federal Government Contracts

Fri, 26 May 2017 08:16:32 EDT

IRVINE, CA--(Marketwired - May 26, 2017) - Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, has received U.S. Federal Government clearance to receive U.S. Federal Government contracts. As the world's largest customer, the U.S. Federal Government issues over $192 billion in contracts and over $450 billion in grants annually.




Ceapro Inc. to Provide a Corporate Update to Shareholders on June 1, 2017

Fri, 26 May 2017 08:05:00 EDT

EDMONTON, ALBERTA--(Marketwired - May 26, 2017) - Ceapro Inc. (TSX VENTURE:CZO) ("Ceapro" or the "Company"), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that Gilles Gagnon, M.Sc., MBA, President and CEO of Ceapro, will provide a corporate update to on site shareholders on Thursday, June 1, 2017 at 8:30 a.m. MDT at the Westin Hotel, Edmonton, AB. The Company's presentation will be followed by the Annual General and Special Meeting of Shareholders to be held at 10:00 a.m. MDT in the Devonian Room of the Westin Hotel. Shareholders are invited to breakfast prior to the meeting at 7:30 a.m. MDT.




Beleave Provides Corporate Update and Outlook After Receiving License to Cultivate Cannabis

Fri, 26 May 2017 07:00:00 EDT

TORONTO, ON --(Marketwired - May 26, 2017) - Beleave Inc. (CSE: BE) (CSE: BE.CN) (CNSX: BE) ("Beleave" or the "Company") recently received its Health Canada license to cultivate cannabis, and is pleased to provide shareholders with a corporate update that includes an overview of the Company's outlook for the remainder of the year.




The Hydroponics Company Limited Secures Strategic Alliance with US-based pharmaceutical company Phoenix Life Sciences to develop medicinal cannabis internationally

Fri, 26 May 2017 03:30:00 EDT

SINGAPORE--(Marketwired - May 26, 2017) - The Hydroponics Company Limited (ASX: THC) ("THC" or "the Company") is pleased to announce that it has signed an exclusive joint venture agreement with Colorado-based healthcare solutions company Phoenix Life Sciences Inc to cooperatively research, develop, manufacture, distribute and sell medicinal cannabis products in Australia and internationally.




Lion Biotechnologies Announces Departure of Chief Financial Officer

Thu, 25 May 2017 16:45:00 EDT

SAN CARLOS, CA--(Marketwired - May 25, 2017) - Lion Biotechnologies, Inc. (NASDAQ: LBIO), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that Gregory Schiffman, Chief Financial Officer, has decided to leave the company for personal reasons, preventing him from commuting from his residence in Portland, OR to the Company's corporate headquarters in San Carlos, CA. Mr. Schiffman will remain in his current role until June 22, 2017. A search for a new CFO is underway through a recruitment agency.




Rennova Health Postpones Special Meeting of Stockholders to June 2, 2017

Thu, 25 May 2017 16:15:00 EDT

WEST PALM BEACH, FL--(Marketwired - May 25, 2017) - Rennova Health, Inc. (NASDAQ: RNVA), (NASDAQ: RNVAZ) ("Rennova" or the "Company"), a vertically integrated provider of industry-leading diagnostics and supportive software solutions to healthcare providers, announces the postponement of its Special Meeting of stockholders that was to have taken place originally on May 19, 2017, and which was subsequently postponed to May 26, 2017. The second postponement is necessary because a quorum of shares represented at the meeting continues not to be achieved. The new date for the Special Meeting is June 2, 2017 at 11:00 a.m. Eastern time and it will take place at the offices of Shutts & Bowen LLP, 525 Okeechobee Boulevard, Suite 1100, West Palm Beach, FL 33401. The record date of April 21, 2017 remains unchanged.




Trillium Announces Proposed Public Offering

Thu, 25 May 2017 16:01:00 EDT

TORONTO, ONTARIO--(Marketwired - May 25, 2017) - Trillium Therapeutics Inc. (TSX:TRIL)(NASDAQ:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has commenced a public offering of its common shares and Series II Non-Voting Convertible First Preferred Shares. The Series II Non-Voting Convertible First Preferred Shares are being offered to investors whose purchase of common shares in the offering may result in such investor, together with its affiliates and certain related parties, beneficially owning more than 4.99% of the Company's outstanding common shares following the consummation of the offering. The Company also intends to grant the underwriters a 30-day option to purchase from it up to an additional 15% of the common shares offered in the offering.




Bio-IT World Announces 2017 Best Practices Awards Winners

Thu, 25 May 2017 13:11:36 EDT

Awarding outstanding examples of technology innovation in the life sciences, from basic R&D to translational medicine since 2003




SANUWAVE Announces Appointment of LITHOMED as Distributor for Orthopedics Products in Taiwan

Thu, 25 May 2017 13:00:00 EDT

SANUWAVE Completes Extensive Search and Appoints LITHOMED as Distributor for Company's Orthopedic Product(s) in Taiwan; Minimum Order Value $500,000




NSAV Announces FINRA Approval and Effectiveness of Stock Dividend

Thu, 25 May 2017 09:24:03 EDT

CRESCO, PA--(Marketwired - May 25, 2017) - Net Savings Link, Inc. (OTC: NSAV), announced today that FINRA has approved and made effective the Company's previously announced 10% common stock dividend, which has a record date of June 1, 2017. The public is advised that the final day to purchase NSAV shares in order to receive the dividend is Friday, May 26, 2017.




Clinical Trial Evaluating the Effect of Prolact CR(R) on Length of Stay and Bronchopulmonary Dysplasia Among Very Low Birth Weight Infants Surpasses the Halfway Point

Thu, 25 May 2017 09:05:00 EDT

DUARTE, CA--(Marketwired - May 25, 2017) - Prolacta Bioscience®, the pioneer in human milk-based neonatal nutritional products for premature infants, announced today that it passed the halfway point in a clinical trial evaluating the effect of adding Prolact CR®, a caloric fortifier made from 100 percent human milk cream, to an exclusive human milk-based diet (EHMD)1 for very low birth weight (VLBW) premature infants. The study is evaluating the length of stay and incidence of bronchopulmonary dysplasia (BPD) and has enrolled 127 of the 210 participants weighing between 500 and 1,250g (1 lb 1 oz to 2 lbs 12 oz).




i2b2 Foundation and tranSMART Foundation Merge to Become the i2b2 tranSMART Foundation

Thu, 25 May 2017 09:00:00 EDT

New Organization Focused on Realizing the Promise of Precision Medicine




The Life Sciences Report Interviews H.C. Wainwright Analyst Ed Arce

Thu, 25 May 2017 08:45:00 EDT

SAN FRANCISCO, CA--(Marketwired - May 25, 2017) - NASH is an epidemic in the U.S., with more than 100 million people believed to be affected. Yet no FDA-approved treatments are available, with the exception of liver transplantation for end-stage disease. In part two of his interview with The Life Sciences Report, Ed Arce, managing director in equity research and senior analyst covering companies in the biopharmaceuticals and specialty pharmaceuticals sectors for H.C. Wainwright, and organizer of the recent inaugural NASH Investor Conference, says that small companies are rushing to fill the pipeline, with numerous compounds in trials.




The Life Sciences Report Examines Viveve Medical's Record-Breaking Quarter

Thu, 25 May 2017 08:45:00 EDT

SAN FRANCISCO, CA--(Marketwired - May 25, 2017) - Viveve Medical Inc.'s (NASDAQ: VIVE) Q1/17 results beat expectations, an accomplishment that was welcomed by several industry analysts.




Rennova Health Names Michael Pollack Interim Chief Financial Officer

Thu, 25 May 2017 08:30:00 EDT

WEST PALM BEACH, FL--(Marketwired - May 25, 2017) - Rennova Health, Inc. (NASDAQ: RNVA), (NASDAQ: RNVAZ) ("Rennova" or the "Company"), a vertically integrated provider of industry-leading diagnostics and supportive software solutions to healthcare providers, announces the appointment of Michael Pollack, CPA as Interim Chief Financial Officer. Mr. Pollack brings approximately 30 years of corporate finance, reporting and consulting experience to Rennova, working with publicly traded and privately held companies with a particular focus on healthcare. Since 2005 Mr. Pollack has been with KBL, LLP, a certified public accounting and business advisory firm, most recently serving as Partner-in-Charge of KBL's audit quality and control, and the Partner-in-Charge of KBL's Public Company (SEC) Practices Group.




UPDATE -- Golden Leaf to Hold Shareholder Call to Review First Quarter 2017 Results

Thu, 25 May 2017 08:00:00 EDT

TORONTO, ON--(Marketwired - May 25, 2017) - Golden Leaf Holdings Ltd. ("GLH" or the "Company") (CSE: GLH) (CSE: GLH.CN) (CNSX: GLH) (OTCQB: GLDFF), a leading cannabis oil solutions company built around recognized brands, today announced that it will hold a shareholder call to review first quarter 2017 results for the period ended March 31, 2017, at 4:15 pm ET on Tuesday, May 30, 2017.




BioSyent Releases Q1 2017 Results

Thu, 25 May 2017 08:00:00 EDT

TORONTO, ONTARIO--(Marketwired - May 25, 2017) - BioSyent Inc. ("BioSyent") (TSX VENTURE:RX) released today a summary of its financial results for the three months ended March 31, 2017. Key highlights include:




Pharmaceutical Case Studies Illustrating Data Analytics Strategies: New Webinar Hosted by Xtalks

Thu, 25 May 2017 07:30:00 EDT

Extracting the Most Value from Your Data Assets




Uncover Pharmacovigilance Insights with Data Discovery and Active Surveillance, New Webinar Hosted by Xtalks

Thu, 25 May 2017 07:00:00 EDT

Third in the series Four Steps to Shorten Your Clinical Trials with Informatics




Revive Therapeutics Ltd. Announces Results for the Three and Nine Months Ended March 31, 2017

Thu, 25 May 2017 07:00:00 EDT

TORONTO, ONTARIO--(Marketwired - May 25, 2017) - Revive Therapeutics Ltd. ("Revive" or the "Company") (TSX VENTURE:RVV) (OTCQB:RVVTF) announced today its results for the three and nine months ended March 31, 2017. The unaudited condensed interim consolidated financial statements and Management's Discussion and Analysis for the period may be viewed on SEDAR at www.sedar.com.




ContraFect Announces Initiation of Phase 2 Study Evaluating CF-301 in Patients with Staphylococcus aureus Bacteremia

Thu, 25 May 2017 07:00:00 EDT

YONKERS, NY--(Marketwired - May 25, 2017) - ContraFect Corporation (NASDAQ: CFRX), a biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious diseases, today announced the initiation of an international Phase 2 study evaluating its first-in-class lysin, CF-301, as a potential treatment of Staphylococcus aureus (Staph aureus) bacteremia including right sided endocarditis. Staph aureus bacteremia and endocarditis are serious life threatening infections, associated with substantial morbidity and mortality despite currently available conventional antibiotics. This multicenter, randomized, double-blind, placebo-controlled study is designed to evaluate the potential for CF-301 to be used in addition to standard-of-care (SOC) antibiotics to significantly improve clinical success rates compared to SOC antibiotics alone. Safety, tolerability, and pharmacokinetics of CF-301 will also be evaluated in the study. The company expects to announce top line results in Q4 2018.




Chinese OEMs Qualify LFS Scintillation Crystals for use in Positron Emission Tomography Medical Scanning Devices

Thu, 25 May 2017 03:15:00 EDT

SINGAPORE--(Marketwired - May 25, 2017) - Zecotek Photonics Inc. (TSX VENTURE: ZMS) (FRANKFURT: W1I) (OTC PINK: ZMSPF), a developer of leading-edge photonics technologies for healthcare, industrial and scientific markets, is pleased to announce that two additional Chinese, tier 1 positron emission tomography (PET) OEM integrators have successfully tested and qualified its patented LFS scintillation crystals for use in their current product lines of PET medical scanners.




Global Pharma Teams Likely to Increase Outsourced Patient Adherence Personnel

Wed, 24 May 2017 17:42:00 EDT

Approximately 50% of surveyed global patient adherence teams report increasing outsourced FTEs




Thomas B. King Joins VIVUS' Board of Directors

Wed, 24 May 2017 16:15:00 EDT

CAMPBELL, CA--(Marketwired - May 24, 2017) - VIVUS, Inc. (NASDAQ: VVUS) (the "Company"), announced today that Thomas B. King has been appointed to VIVUS' board of directors. Mr. King's nearly 40 years of pharmaceutical experience ranges from large to development-stage pharmaceutical companies.




Bio-Rad Introduces Enhanced Options with its IH-Com Data Management Software for Managing Patient Results with the IH-1000 System

Wed, 24 May 2017 16:15:00 EDT

HERCULES, CA--(Marketwired - May 24, 2017) - Bio-Rad Laboratories, Inc. (NYSE: BIO) (NYSE: BIOb), a global provider of life science research and clinical diagnostic products, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for enhanced capability with its IH-Com data management software to manage patient results with the company's IH-1000 automated blood typing instrument.




UPDATE - CROS NT Announces Extended Partnership With Medidata -- Deploys RaveX

Wed, 24 May 2017 15:42:29 EDT

MAIDENHEAD, UNITED KINGDOM and CHAPEL HILL, NC--(Marketwired - May 24, 2017) - CROS NT today announced the go-live of its RaveX team in an extension of the company's partnership with Medidata.




Shema Kolainu's Workshop: The Behavioral Management

Wed, 24 May 2017 15:15:45 EDT

NEW YORK, NY--(Marketwired - May 24, 2017) - Shema Kolainu - Hear Our Voices, the school and center for autism an educational organization dedicated to the support and education of individuals with autism spectrum disorders (ASD) held its 8th free autism workshop at Pennsylvania Hotel in New York City on Tuesday. April's workshop focused on how to conduct basic functional analysis to assess the function of behaviors in multiple settings and include the special needs child in family outings. As usual, Autistics, their families; and therapists, professors, and other health care professionals were present at our Tuesday's program.




KBI Biopharma selects The Windshire Group's and Simplyfeye's ProcessPad(TM) continued process verification solution

Wed, 24 May 2017 12:33:58 EDT

BOSTON, MA--(Marketwired - May 24, 2017) - The Windshire Group, LLC and Simplyfeye Inc. are pleased to announce KBI Biopharma, Inc. will deploy ProcessPadtm for its data analysis, management and reporting solution for process development, product scale-up and commercial manufacturing operations. KBI is a leading CDMO (contract development and manufacturing organization) and has served over 250 clients worldwide, including most of the top ten pharmaceutical companies.




CORRECTION - Cosmos Holdings, Inc. Announces first Quarter 2017 Results

Wed, 24 May 2017 11:40:00 EDT

CHICAGO, IL--(Marketwired - May 24, 2017) - In the news release, "Cosmos Holdings, Inc. Announces first Quarter 2017 Results," issued yesterday, May 23, by Cosmos Holdings (OTCQB: COSM), we are advised by the company that the subhead should read "Revenue Improved 262% and Gross Profit Improved 315% compared to the three months ended March 31, 2016." The "revenue improved" and "gross profit" percentages in the second paragraph were also updated. Complete corrected text follows.




NSAV Announces Update on OTC Reporting Status

Wed, 24 May 2017 10:36:25 EDT

CRESCO, PA--(Marketwired - May 24, 2017) - Net Savings Link, Inc. (OTC: NSAV), a legal medical cannabis technology and advisory company, announced today that it will continue to operate as an SEC fully reporting company. In order to expedite this process, NSAV has retained the services of PCAOB auditor, Paritz & Company, P.A., a New Jersey-based accounting and auditing firm. The Company views this move as a major step to becoming fully SEC reporting and greatly enhancing the public image of NSAV. The Company filed a Form 8-K with the SEC last week to report this development.




Ovation Receives $1.5M in Funding and Launches Collaboration with iGeneTRAiN

Wed, 24 May 2017 08:57:06 EDT

CAMBRIDGE, MA--(Marketwired - May 24, 2017) -  Ovation Life Sciences, LLC (Ovation) announced today the receipt of 1.5 million dollars in funding from StageDotO, and existing investors, including Longfellow Ventures. The company will use the funds to continue the development of its next-generation scientific data-layer-as-a-service platforms, built to accelerate the progress of life science by improving how the story of scientific data is told. Ovation also announced a partnership with iGeneTRAiN to use Ovation Research to maximize collaboration capabilities across iGeneTRAiN's transplant consortium. The announcement was made today at the 2017 BioIT World Conference and Expo, www.bio-itworldexpo.com.




PeopleFluent Named an Enterprise Learning Market Leader by Aragon Research

Wed, 24 May 2017 08:30:00 EDT

Integrated video learning, social collaboration capabilities, and strength of Talent Management suite cited as key differentiators




Rennova Health Reports First Quarter 2017 Financial Results

Wed, 24 May 2017 08:30:00 EDT

WEST PALM BEACH, FL--(Marketwired - May 24, 2017) - Rennova Health, Inc. (NASDAQ: RNVA) (NASDAQ: RNVAZ) ("Rennova" or the "Company") reports financial results for the first quarter ended March 31, 2017 and provides a business update.




How to Upgrade Kombucha and Functional Beverage, Food, Supplement Products with Symbiotic Botanical Fermentation, New Webinar Hosted by Xtalks

Wed, 24 May 2017 08:18:30 EDT

TORONTO, ON--(Marketwired - May 24, 2017) - During a live broadcast, industry expert Chantale Houle, President of Kefiplant, will discuss the upcoming market opportunities for kombucha and botanicals.




The Good, the Bad, the Necessary in Rare Disease Studies, New Webinar Hosted by Xtalks

Wed, 24 May 2017 08:10:14 EDT

Live session on June 8, 2017 features expert panel from INC Research discussing the why, where, when and how a rare disease drug is intended to be used subsequent to approval and the importance of beginning with the end in mind




Nabsys Demonstrates High-Definition Whole Genome Mapping Performance Capturing Structural Variants in Microbial and Human Genomes, Plans Beta Program

Wed, 24 May 2017 08:01:00 EDT

Talks and Papers Previewed at PMWC 2017 and SFAF Conferences Advance Nabsys' Mission to Democratize Structural Information




BioVie Announces Issuance of US Patent Covering BIV201 for the Treatment of Ascites Due to Liver Cirrhosis

Wed, 24 May 2017 08:00:00 EDT

BEVERLY, MA--(Marketwired - May 24, 2017) - BioVie Inc. (OTCQB: BIVI), a clinical-stage company focused on the discovery, development, and commercialization of innovative drug therapies for liver disease, today announced that the US Patent and Trademark Office (USPTO) has issued US Patent No. 9,655,945 covering the Company's new drug candidate BIV201 in development for the treatment of ascites in patients with advanced liver cirrhosis.




NEXT Biometrics Announces Interim 1st Quarter Results; CEO Ritu Favre Discusses 2017 Outlook

Wed, 24 May 2017 07:47:18 EDT

OSLO, NORWAY--(Marketwired - May 24, 2017) - NEXT Biometrics Group ASA (Oslo Bors: NEXT) today announced interim results for the first quarter ended March 31, 2017 and outlined its strategic focus for the 2017 over the next 3 to 9 months of 2017. NEXT, the leader in high-quality low-cost rigid and flexible fingerprint sensors, summarized first quarter 2017 highlights:




Easton Pharmaceuticals Announces It Has Signed an LOI to Acquire An Interest in a 45 Acre Parcel for the Cultivation of Medical Marijuana in Toronto, Canada; Wholly Owned Subsidiary, iBliss in Birmingham's UK Vaper Expo

Wed, 24 May 2017 07:28:28 EDT

TORONTO, ON--(Marketwired - May 24, 2017) -  Easton Pharmaceuticals, Inc. (OTC PINK: EAPH) is pleased to announce that it has signed a Letter of Intent with Canadian Alliance Group to acquire an interest in their 45 acre fully owned parcel of land for the cultivation, production and sale of medical marijuana to the cannabis industry. Easton's wholly owned subsidiary, iBliss Inc. is currently in Birmingham, UK for this weekend's Vaper expo.




Tauriga Sciences Inc. Assigned Trial Date on November 6, 2017 from United States District Court New Jersey

Wed, 24 May 2017 07:15:00 EDT

TRENTON, NJ--(Marketwired - May 24, 2017) - Tauriga Sciences Inc. (OTC PINK: TAUG) ("Tauriga" or "the Company"), a company engaged in the building of life sciences businesses and technologies, has today announced that the Trial date has been scheduled for November 6, 2017 concerning its ongoing federal litigation against its predecessor audit firm Cowan Gunteski & Co. P.A. ("Cowan Gunteski"). 




Government Account Manager Staffing Levels Surpass Those of Pharmacy Account Managers in Global Pharma Market Access Teams

Tue, 23 May 2017 18:26:00 EDT

RESEARCH TRIANGLE PARK, NC--(Marketwired - May 23, 2017) - Market access teams across Top 10, Top 50 and small pharmaceutical companies are more likely to employ higher numbers of full-time equivalents (FTEs) to support government accounts compared to pharmacy accounts, according to a recently released study by business intelligence provider, Cutting Edge Information.




Tetra Bio-Pharma Signs Definitive Agreement for Two Products with Panag Pharma

Tue, 23 May 2017 16:00:00 EDT

OTTAWA, ONTARIO--(Marketwired - May 23, 2017) - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (CSE:TBP)(CSE:TBP.CN)(CNSX:TBP)(OTCQB:TBPMF), announced today it has signed a definitive agreement with Panag Pharma Inc. for the development and commercialization of novel cannabinoid based formulations for the treatment of pain and inflammation. Combined total market potential of both products in the USA in 2014 is estimated over US$5.5 billion. The recent press release on May 17th for the filing of a patent in ocular disease combined with the patents from Panag in the ocular space make this agreement very lucrative.




SANUWAVE Health Announces Shock Wave Scientific Program in Milan, Italy Conducted by Medical Advanced Technologies, 26 May, 2017

Tue, 23 May 2017 15:00:00 EDT

SUWANEE, GA--(Marketwired - May 23, 2017) - SANUWAVE Health, Inc. (OTCQB: SNWV) is pleased to announce that the company's exclusive distributor in Italy, Medical Advanced Technologies S.R.L. (MATEK) is sponsoring a one day scientific program to be conducted in Milan, Italy on May 26, 2017. This program, Workshop@Rooftop, will be held at the exclusive Hotel The Square in Milan. MATEK has been one of SANUWAVE's most active partners in promoting both dermaPACE® and orthoPACE® in Europe. Their innovative and proactive approach towards promoting dermaPACE and orthoPACE is reflected in this program which will assemble some of the most accomplished medical researchers and medical practitioners in Italy. The program will discuss the newest clinical information related to the mechanism of action for SANUWAVE's product line and to discuss clinical case-studies and on-going research in the field of extracorporeal shock wave technology (ESWT) and in particular the use of dermaPACE for wound indications and orthoPACE for orthopedic indications. Specific topics include:




Coliprotec(R) F4/F18 est lancé dans l'Union européenne par Elanco : Prevtec Microbia livre un million de doses

Tue, 23 May 2017 14:26:22 EDT

MONTRÉAL, QUÉBEC--(Marketwired - 23 mai 2017) - Prevtec Microbia Inc. (« Prevtec ») est heureuse d'offrir un compte rendu du lancement commercial de son vaccin bivalent Coliprotec® F4/F18 dans l'Union européenne. Coliprotec® F4/F18 est un produit phare contre la diarrhée post-sevrage chez les porcs.




Coliprotec(R) F4/F18 is launched in the EU through Elanco: Prevtec Microbia delivers a million doses

Tue, 23 May 2017 14:25:28 EDT

MONTREAL, QUEBEC--(Marketwired - May 23, 2017) - Prevtec Microbia Inc. ("Prevtec") is pleased to provide an update on the commercial launch of its bivalent vaccine Coliprotec® F4/F18 in the European Union, a front line product against post weaning diarrhea (PWD) in pigs.




Cosmos Holdings, Inc. Announces first Quarter 2017 Results

Tue, 23 May 2017 12:28:12 EDT

Revenue Improved 362% and Gross Profit Improved 415% compared to the three months ended March 31, 2016




Science Exchange Invited to Speak at the Novartis Institutes for Biomedical Research (NIBR) Seminar

Tue, 23 May 2017 12:00:00 EDT

Elizabeth Iorns, Ph.D., Founder and CEO of Science Exchange will present the Reproducibility Project: Cancer Biology




IBM and the tranSMART Foundation Bring Translational Medicine Data to Scientists

Tue, 23 May 2017 10:06:04 EDT

tranSMART 16.2 accelerated using IBM Power8 Servers and Elastic Storage Server (ESS) is now available to 150+ Pharmaceutical Users




Protext Mobility Completes Name Change to Protext Pharma and Provides Update on Medical Cannabis License

Tue, 23 May 2017 10:00:00 EDT

BOCA RATON, FL--(Marketwired - May 23, 2017) - Protext Pharma, Inc. (OTC PINK: TXTM) ("Protext" or "the Company"), a biotech company engaged in the development of pharmaceutical applications with highly bioavailable Phytofare® extracts, has announced today that its name change to Protext Pharma, Inc is now effective with the State of Delaware, and is pleased to provide the following shareholders update on its wholly owned subsidiary Cannabis Biosciences. The Company expects to submit the name change to FINRA in the coming days.




Vitargent introduces world's first product safety information platform applying proprietary Testing 2.0 biological testing technology

Tue, 23 May 2017 09:00:00 EDT

Safety of 100-plus edible oils thoroughly examined in breakthrough test




Vaxil Launches Manufacturing of ImMucin Immunotherapy for Upcoming Clinical Trials

Tue, 23 May 2017 08:30:00 EDT

Selected to Present at 2017 Biomed Conference




Nutra Pharma Announces Collaboration with the International Security Group for Development of Nerve Agent Counter Measures

Tue, 23 May 2017 08:30:00 EDT

CORAL SPRINGS, FL--(Marketwired - May 23, 2017) - Nutra Pharma Corporation (OTCQB: NPHC), a biotechnology company marketing Nyloxin® and Pet Pain-AwayT in the over-the-counter (OTC) pain management market, and which is also developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced a collaboration today with International Security Group to develop its nerve agent counter measures.




CROS NT Announces Extended Partnership With Medidata -- Deploys RaveX

Tue, 23 May 2017 08:30:00 EDT

MAIDENHEAD, UNITED KINGDOM and CHAPEL HILL, NC--(Marketwired - May 23, 2017) - CROS NT today announced the go-live of its RaveX team in an extension of the company's partnership with Medidata.




OncBioMune CMO Begins Formulation Work on Tretinoin for Acute Promyelocytic Leukemia

Tue, 23 May 2017 08:30:00 EDT

BATON ROUGE, LA--(Marketwired - May 23, 2017) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a clinical stage biopharmaceutical company engaged in the development of novel cancer products and a proprietary vaccine technology, is pleased to announce that its contract manufacturing organization (CMO) has begun formulation work on tretinoin, also known as all-trans retinoic acid (ATRA), at its state-of-the-art, cGMP-compliant facility in Colombia. Tretinoin is an oral drug for the treatment of Acute Promyelocytic Leukemia (APL). OncBioMune has acquired commercialization rights for tretinoin throughout Mexico, Central America and Latin America from the leading South American CMO.




Golden Leaf to Hold Shareholder Call to Review First Quarter 2017 Results

Tue, 23 May 2017 08:00:00 EDT

TORONTO, ON--(Marketwired - May 23, 2017) - Golden Leaf Holdings Ltd. ("GLH" or the "Company") (CSE: GLH) (CSE: GLH.CN) (CNSX: GLH) (OTCQB: GLDFF), a leading cannabis oil solutions company built around recognized brands, today announced that it will hold a shareholder call to review first quarter 2017 results for the period ended March 31, 2017, at 9:00 am ET on May 26, 2017.




CB Scientific's (CBSC) CannaRAPID an Effective Intervention for Opioid Drug Addiction Patients -- Every Year Close to 28,000 People Die From an Opioid-Related Overdose in America

Tue, 23 May 2017 08:00:00 EDT

DENVER, CO--(Marketwired - May 23, 2017) - CB Scientific, Inc. (OTC PINK: CBSC), a designer, developer and manufacturer of Cannabis Analytical Tools and Devices, Cannabis Medical Delivery Systems and Personal Analytical Kits and Devices, announces today that the Company has developed a novel product medical device portfolio since acquiring Marutronics Medical Devices in February 2017. The company has developed three core platform technologies; CannaRAPIDT, CannaNASALT, and CannaDERMET, focused on precise dosing and controlled release of cannabinoid compounds for patients. CB Scientific developed CannaRAPIDT, a sublingual cannabinoid delivery product, and is gearing up for clinical studies on the use of CannaRAPIDT for treating opioid addiction.




REPROCELL and Fox Chase Cancer Center Partner to Open Multi-Site Biosample Repository in India

Tue, 23 May 2017 07:59:17 EDT

Joint venture provides quality source of clinically annotated tissue specimens from vast Indian population




Moleculin Biotech Issues Shareholder Update on FDA Designation of Orphan Drug and IND Status for Annamycin

Tue, 23 May 2017 07:30:00 EDT

HOUSTON, TX--(Marketwired - May 23, 2017) - Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a preclinical pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center ("MD Anderson"), today announced that it has issued the following letter to its shareholders.




Biomerica to present at the 18th Annual B. Riley & Co. investor conference on May 24, 2017

Tue, 23 May 2017 07:29:00 EDT

IRVINE, CA--(Marketwired - May 23, 2017) - Biomerica Inc. (NASDAQ: BMRA) today announced it will present at the 18th Annual B. Riley institutional investor conference being held May 24-25, 2017 in Santa Monica, CA.




Self-Administration Injection Systems -- A Change in Market Trends Requires a Rethinking of Your Compounds Packaging, New Xtalks Webinar

Tue, 23 May 2017 07:00:00 EDT

Session will offer insight on the advantages of prefilled syringes and cartridges, including the various differentiators of the most commonly used syringe platforms -- pre-sterilized and bulk




Zecotek Delivers Patented LFS Scintillation Crystals to Multiple High Tech Institutions

Tue, 23 May 2017 03:15:00 EDT

SINGAPORE--(Marketwired - May 23, 2017) - Zecotek Photonics Inc. (TSX VENTURE: ZMS) (FRANKFURT: W1I)(OTC PINK: ZMSPF),a developer of leading-edge photonics technologies for healthcare, industrial and scientific markets, is pleased to announce that four prestigious high tech institutions have ordered its patented LFS scintillation crystals for both medical imaging and high energy physics experiments.




Pieris Pharmaceuticals Appoints James Geraghty to its Board of Directors

Mon, 22 May 2017 16:32:41 EDT

BOSTON, MA--(Marketwired - May 22, 2017) - Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer, respiratory and other diseases, announced today that James Geraghty has joined the Company's Board of Directors, bringing the total number of directors to eight.




Three Ogilvy CommonHealth Worldwide executives to speak at the 2017 e-RX and EHR Conference

Mon, 22 May 2017 15:26:51 EDT

PARSIPPANY, NJ--(Marketwired - May 22, 2017) - Ogilvy CommonHealth Worldwide (www.ogilvychww.com), the health behavior change specialists of Ogilvy & Mather (www.ogilvy.com), and a WPP Health & Wellness company (NASDAQ: WPPGY) (www.wpp.com), today announced Angelo Campano, Russell Grimaldi, and Ritesh Patel will present at the 2017 e-RX and EHR Conference on May 23-24, 2017, in Philadelphia, PA.




MyDx Reports First Quarter Results

Mon, 22 May 2017 09:58:42 EDT

Strong Performance of CannaDx Drives Sales Growth, Leading To Positive Cash-Flow Generation




Advantis Corp. Posts Record First Quarter Revenue

Mon, 22 May 2017 09:15:00 EDT

NEWPORT BEACH, CA--(Marketwired - May 22, 2017) - ADVANTIS CORPORATION (OTC PINK: ADVT) filed its first quarter financial report today. The $119,000 of revenue reported is its highest quarterly revenue in company history.




Therapeutic Solutions files new Patent on Augmentation of Anti-Tumor Immunity by Mifepristone and Analogues Thereof

Mon, 22 May 2017 09:00:00 EDT

Company Developing Proprietary Products that Help Immune System Fight Cancer




Sinequa to Exhibit and Present at Bio-IT World on Cognitive Search and Analytics in the Biopharma Industry

Mon, 22 May 2017 09:00:00 EDT

NEW YORK, NY--(Marketwired - May 22, 2017) - Sinequa, a leader in search and analytics, today announced its presence at Bio-IT World Conference & Expo for the fourth consecutive year and a featured speaking slot. The event, taking place May 23-25 in Boston, will bring together more than 3,300 healthcare and IT professionals from across the world to discuss technologies that drive biomedical research, drug discovery and development and clinical and healthcare initiatives.